Search

These findings suggest that tumor cells employ multiple epigenetic and genetic mechanisms to evade immune control

We found two known risk factors in a large cohort of children treated for ALL and identified other factors associated with venous thromboembolism

This systematic review shows that children treated with platinum analogues are at risk of developing hearing loss

In this review, we discuss the different subsets of tumor-infiltrating dendritic cells and their role in anti-tumor immunity

The ANZCHOG-BN is a new biobank network in Australasia that was developed to improve and streamline access to high-quality pediatric and AYA cancer biospecimens

Our findings shed light on the mechanisms of leukemia-induced bone loss

Our data demonstrate that CD8+XCR1neg DCs possess a unique pattern of endocytic receptors and a restricted TLR profile that is particularly enriched for TLR5

Our results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer-immune equilibrium

Our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis

Monoclonal antibodies are revolutionizing the landscape of current cancer treatment, bringing hope to patients with incurable cancers. B7-H3 (CD276) is an attractive therapeutic target for antibody-based therapy due to its low or absent expression in normal tissues and high expression in various types of tumors, including prostate cancer, pancreatic cancer, and high-mortality esophageal squamous cell carcinoma (ESCC). In recent years, various B7-H3-targeting antibodies have been developed for cancer treatment, with a few making their way to clinical trials.